ImmunityBio (NASDAQ:IBRX) Stock Jumps 4.5% – Here’s What Happened

Shares of ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) shot up 4.5% during mid-day trading on Tuesday. The company traded as high as $6.38 and last traded at $6.2520. 1,757,559 shares were traded during mid-day trading, a decline of 91% from the average session volume of 19,836,211 shares. The stock had previously closed at $5.98.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IBRX shares. Wall Street Zen cut ImmunityBio from a “hold” rating to a “sell” rating in a report on Saturday. Jefferies Financial Group upped their price objective on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of ImmunityBio in a research note on Thursday, October 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $16.00 target price on shares of ImmunityBio in a research note on Wednesday, October 14th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Check Out Our Latest Research Report on IBRX

ImmunityBio Price Performance

The stock’s 50-day moving average is $8.55 and its two-hundred day moving average is $7.96. The stock has a market cap of $6.56 billion, a P/E ratio of -5.70 and a beta of 0.17.

Insiders Place Their Bets

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the sale, the director owned 100,309 shares in the company, valued at $1,053,244.50. The trade was a 44.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares of the company’s stock, valued at $29,861,221. This trade represents a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in ImmunityBio by 29.4% during the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after buying an additional 7,736,819 shares during the last quarter. State Street Corp grew its holdings in ImmunityBio by 20.8% during the 2nd quarter. State Street Corp now owns 21,398,438 shares of the company’s stock valued at $187,343,000 after buying an additional 3,690,335 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in ImmunityBio by 27.7% in the 3rd quarter. Goldman Sachs Group Inc. now owns 4,129,906 shares of the company’s stock worth $38,986,000 after acquiring an additional 895,629 shares during the last quarter. Bank of America Corp DE increased its stake in ImmunityBio by 2.7% in the 1st quarter. Bank of America Corp DE now owns 2,447,843 shares of the company’s stock worth $18,775,000 after acquiring an additional 65,340 shares during the last quarter. Finally, SEB Asset Management AB purchased a new stake in shares of ImmunityBio during the 1st quarter worth approximately $18,770,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

Featured Articles

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.